Biocompatibility Evaluation Under ISO 10993-1 for US Submissions

1. Key takeaways

The place of biocompatibility evaluation in a US submission is this: ISO 10993-1 provides the framework; the endpoints requiring evaluation are determined according to the device’s nature of contact (surface-contacting, externally communicating, or implant) and its duration of contact (limited, prolonged, or permanent); testing is then completed under the relevant ISO 10993 part standards; and the conclusions are integrated into the risk management documentation. Read in that order, the evaluation is a structured reasoning exercise rather than a shopping list of assays — and the difference shows up both in the cost of the program and in how the dossier reads under review.

• Contact nature and contact duration come first; the endpoint list follows from them, not the other way around.
• Testing is carried out under the relevant ISO 10993 part standards, with ISO 10993-1 supplying the evaluation framework.
• An equivalence argument against the predicate can reduce new testing, provided materials, processes, and sterilization are all unchanged.
• The evaluation reasoning, not the test panel itself, is what a reviewer reads first; the documentation of that reasoning is part of the deliverable.
• Sterilization residuals, leachables, and degradation products belong inside the evaluation, and the conclusions must trace into the risk management documentation and the quality system records.

2. Legal basis

The instruments listed below, as cited in the source material, frame where biocompatibility obligations arise and how they connect to the rest of the submission.

3. Expert insights

Insight one: ISO 10993-1 is a process standard for biological evaluation, not a test checklist.

The core of ISO 10993-1 is to conduct the evaluation as part of the risk management process: first judge the nature and duration of the device’s contact with the body, and only then decide the evaluation endpoints. Sending a device straight to the full panel of biological tests is a common and expensive waste — it inverts the logic of the standard, spending money on endpoints that the contact profile may not require while leaving the reasoning that connects tests to risks undocumented. The framework exists precisely to prevent that inversion, and following its sequence is the single largest cost lever in the whole evaluation.

Insight two: an equivalence argument against the predicate can reduce the testing volume.

Where the device under submission uses the same materials, the same manufacturing processes, and the same sterilization method as the predicate, existing data can be cited through an equivalence argument, reducing the need for new testing. But the equivalence chain breaks the moment the material source, the additives, or the processes change. Each of those three elements therefore has to be verified item by item before any data are borrowed, because a borrowed dataset resting on a broken chain is worse than no dataset at all: it documents a comparison the device does not actually satisfy. The verification is cheap at planning stage and unrepeatable once the report has been issued on the wrong footing.

Insight three: sterilization residuals and leachables are the items most often corrected.

Ethylene oxide residuals, material changes following irradiation, leachables, and degradation products all belong within the scope of the biocompatibility evaluation. Omitting this part is a common reason for technical deficiencies raised during review. The reason is structural rather than careless: these exposures arise from manufacturing and sterilization choices, not from the material list alone, so an evaluation scoped only to constituent materials will systematically miss them. Treating sterilization as an input to biocompatibility, rather than a separate workstream, is the fix.

Insight four: after the QMSR takes effect, the biocompatibility evidence chain must cross-reference the design control records of ISO 13485:2016.

Under 21 CFR 820, effective from 2026-02-02 and incorporating ISO 13485:2016 by reference, the biological evaluation conclusions presented in the submission must be traceable to corresponding design input, design output, and design verification records within the quality system. The submission and the system records are therefore two views of the same evidence, and a biocompatibility report that cannot be tied back to design controls will be inconsistent with the establishment’s own documentation when inspection or review looks for the connection. Building the index while the evaluation is being written is far cheaper than reconstructing it under deficiency.

4. Practical recommendations

• Determine the nature and duration of contact first, then fix the evaluation endpoints, and only then schedule testing.
• Compile the material list — including additives, colorants, and coatings — completely in one pass, to avoid supplementary testing later.
• When making the equivalence argument against the predicate, verify materials, processes, and sterilization item by item.
• Bring sterilization residuals and leachables into the scope of the evaluation.
• Build a two-way index between the biological evaluation report and the design control records within the quality system.

5. Verification checklist

• □ The nature of contact and the duration of contact have been determined
• □ The list of evaluation endpoints has been drawn up from that determination
• □ The material list, including additives and coatings, has been compiled completely
• □ The equivalence argument against the predicate has been verified item by item for materials, processes, and sterilization
• □ Sterilization residuals and leachables have been brought within the evaluation scope
• □ A two-way index has been established between the biological evaluation report and the design control records of the quality system

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com